C07D317/66

CXCR6 SULFONAMIDE COMPOUNDS

Provided are sulfonamide compounds having formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.

CXCR6 SULFONAMIDE COMPOUNDS

Provided are sulfonamide compounds having formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.

BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF
20230339919 · 2023-10-26 · ·

Disclosed in the present invention are a compound represented by formula Ib or IIb, a cis or trans isomer, enantiomer, diastereomer, racemate, tautomer, solvate, hydrate, and pharmaceutically acceptable salt thereof, or a mixture thereof, a pharmaceutical composition containing the compound, and a use of the compound as a GPR40 agonist, wherein n, E, G.sup.1, L.sup.1, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.5b, R.sup.6, R.sup.7, X.sup.5, X.sup.6, X.sup.7, Y, Y.sup.1, Z, Z.sup.1, and the possible isotopic substitution label of each element in the compound are as defined in the description.

##STR00001##

BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF
20230339919 · 2023-10-26 · ·

Disclosed in the present invention are a compound represented by formula Ib or IIb, a cis or trans isomer, enantiomer, diastereomer, racemate, tautomer, solvate, hydrate, and pharmaceutically acceptable salt thereof, or a mixture thereof, a pharmaceutical composition containing the compound, and a use of the compound as a GPR40 agonist, wherein n, E, G.sup.1, L.sup.1, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.5b, R.sup.6, R.sup.7, X.sup.5, X.sup.6, X.sup.7, Y, Y.sup.1, Z, Z.sup.1, and the possible isotopic substitution label of each element in the compound are as defined in the description.

##STR00001##

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

PREPARATION OF SECONDARY AMINES WITH ELECTROPHILIC N-LINCHPIN REAGENTS

In one aspect, the present disclosure provides methods of preparing a secondary amine. In some embodiments, the secondary amine comprises two different groups or two identifical groups. Also provided herein are compositions for use in the preparation of the secondary amine.

Compounds and methods for inducing chondrogenesis

Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.